Health Care · Services-Medical Laboratories

CSTL CASTLE BIOSCIENCES INC SEC Filings & Insider Trading Activity 2026

company
CIK 1447362138 filings
Russell 2000

CSTL at a glance

CASTLE BIOSCIENCES INC (CSTL, SEC CIK 1447362) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), CASTLE BIOSCIENCES INC (CSTL) reported revenue of $344.2 million (up 3.7% from FY2024) and a net loss of $24.2 million. Diluted EPS was -$0.83.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding CASTLE BIOSCIENCES INC (CSTL) shares worth $419.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MAETZOLD DEREK J on November 16, 2026 of 1,396 shares at $32.92 per share.
  • In the last 90 days, CSTL insiders reported 0 open-market purchases ($0) and 58 open-market sales ($6.1M) on Form 4, a net sale of $6.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$344.2M
+3.7% vs prior year
Insiders · 90 days
0 buys · 58 sells
Net −$6.1M
13F holders
29 funds
$419.1M · +1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 7.01 · Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes overall from the 2025 10-K, aside from updates described below
  • Accumulated deficit $245.0 million at September 30, 2026, versus $224.3 million at December 31, 2025
  • Medicare reimbursement discontinuation for DecisionDx-SCC continued reducing its revenue contribution in 2026
  • New geopolitical risk: February 2026 U.S.-Iran conflict and Strait of Hormuz disruption threaten energy supplies and shipping routes
  • Macroeconomic risk: inflation increased personnel and laboratory supply costs, potentially limiting liquidity and capital access

Management Discussion & Analysis

  • Q3 revenue $102.9M, up 23.9% YoY from $83.0M
  • Gross margin 74.7% vs 74.7% YoY; operating loss $2.7M vs $6.8M
  • Best segment: non-dermatologic revenue $55.0M, up $20.5M; TissueCypher volume up 47%
  • Worst segment: dermatologic revenue $47.9M, down $0.6M; DecisionDx-SCC affected by lost Medicare coverage
  • Cash $78.0M vs $116.7M at year-end; nine-month operating cash flow $12.8M, capital expenditures $28.6M

AI summary of the CSTL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor presentation released November 5, 2026 under Regulation FD
  • Slides may guide management discussions in future investor meetings

Item EX-99.1: Item EX-99.1

  • Q3 revenue $102.9M, up 24% YoY, led by TissueCypher reports up 47% to 15,574
  • 2026 revenue guidance raised to $385M-$395M from $365M-$375M, signaling stronger near-term demand

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026
  • Press release Exhibit 99.1 contains the underlying results and management commentary

Item EX-99.2: Item EX-99.2

  • Q3 2026 revenue $102.9M, total test volume 32,431, adjusted EBITDA $12.7M, and adjusted gross margin 77%
  • Full-year 2026 revenue guidance raised to $385M-$395M, up $45M at the midpoint since February
Filed Jul 30, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 released July 30, 2026
  • Detailed financial results and management commentary contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $103.5M, up from $86.2M, with core test reports up 32%
  • TissueCypher reports surged to 14,988 from 9,170, offsetting modest DecisionDx-Melanoma growth

Item 7.01: Regulation FD Disclosure

  • Exhibit 99.2 presents Castle Biosciences’ investor presentation
  • Management may use the materials in future investor meetings

Item EX-99.2: Item EX-99.2

  • 2Q26 revenue $103.5M, adjusted EBITDA $12.4M and operating cash flow $15.2M, demonstrating profitability and cash generation
  • 2026 revenue guidance raised to $365-375M from $345-355M, signaling stronger expected demand and execution
Filed May 29, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders elected Ellen Goldberg, Miles D. Harrison, and Tiffany P. Olson as Class I directors through 2029
  • Director support varied, with Tiffany P. Olson receiving 14,380,655 votes for versus 8,192,776 withheld

AI summaries of CSTL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CSTL

Don't miss the next CSTL filing

  • Alerts as it files. A push when CSTL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CSTL, by share count.
  • Ask anything. An AI agent that reads every CSTL filing and answers with sources.

CSTL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
BRADBURY DANIELGNov 17, 2026-
MAETZOLD DEREK JSellNov 16, 2026$32.92
MAETZOLD DEREK JSellNov 16, 2026$32.92
MAETZOLD DEREK JSellNov 16, 2026$32.92
Juvenal Tobin WMNov 11, 2026$29.50
Juvenal Tobin WMNov 11, 2026-
Juvenal Tobin WSellNov 11, 2026$35.04
Juvenal Tobin WSellNov 11, 2026$35.07

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$332.1M$344.2M
Operating Income-$8.7M-$42.8M
Net Income-$57.5M$18.2M-$24.2M
Op. Margin-2.6%-12.4%
Net Margin-5.5%-7.0%
Balance Sheet
Total Assets-$531.2M$578.6M
Equity$391.3M$455.8M$470.9M
ROE-14.7%4.0%-5.1%
Per Share
EPS$-2.14$0.62$-0.83
Cash Flow
Operating CF-$5.6M$64.9M$64.3M
CapEx-$28.3M$36.0M

Source: XBRL data in CASTLE BIOSCIENCES INC (CSTL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CSTL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CSTL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$419.1M
Q2 202628$274.8M
Q1 202627$287.2M
Q4 202527$468.6M
Q3 202527$292.2M
Q2 202527$270.9M
Q1 202525$175.9M
Q4 202419$214.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 209 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CSTL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 18, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Nov 4, 2026--
4Oct 30, 2026--
4Oct 28, 2026--
4Oct 21, 2026--
4Oct 14, 2026--
4Oct 7, 2026--
4Oct 5, 2026--
4Oct 1, 2026--
4Sep 23, 2026--
4Sep 16, 2026--
4Sep 15, 2026--
4Sep 3, 2026--
4Sep 2, 2026--
4Sep 1, 2026--
4Aug 27, 2026--
4Aug 26, 2026--
4Aug 19, 2026--
4Aug 18, 2026--
4Aug 18, 2026--

Related Health Care companies

All Health Care →

CSTL SEC filings: frequently asked questions

Are CSTL insiders buying or selling?

In the last 90 days, CASTLE BIOSCIENCES INC (CSTL) officers, directors and 10% owners reported no open-market purchases and 58 open-market sales worth $6.1 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CSTL stock?

As of September 30, 2026, the largest CASTLE BIOSCIENCES INC (CSTL) holders among the 13F filers tracked by SignalX were BlackRock ($122.7 million), Principal Financial Group ($53.3 million), Vanguard Capital Management LLC ($44.0 million), State Street Corp ($28.6 million), Vanguard Portfolio Management LLC ($25.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CSTL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), CASTLE BIOSCIENCES INC (CSTL) reported revenue of $344.2 million (up 3.7% from FY2024) and a net loss of $24.2 million. Diluted EPS was -$0.83. The figures come from the XBRL data in the 10-K.

What did CSTL report in its latest 8-K?

CASTLE BIOSCIENCES INC (CSTL) filed an 8-K on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Investor presentation released November 5, 2026 under Regulation FD.

What are the latest CSTL SEC filings?

CASTLE BIOSCIENCES INC (CSTL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.

What is CSTL's SEC CIK number?

CASTLE BIOSCIENCES INC (CSTL)'s SEC Central Index Key (CIK) is 1447362. EDGAR lists every CSTL filing under that number.

Ask anything about CSTL

The research agent reads CSTL's filings, financials, insider trades and 13F holders, then answers with sources.